The R-Pharm group of companies announced the registration in the Republic of Kazakhstan of its own drug Artlegia (olokizumab) for the treatment of rheumatoid arthritis, and is also included in the treatment guidelines of the Ministry of Health of the Russian Federation. coronavirus infection.
Artlegia is the world’s first registered monoclonal antibody that directly blocks IL-6 instead of its receptor.
The efficacy and safety of Artlegia (olokizumab) has been confirmed within the framework of CREDO, a long-term international research program involving more than 2400 patients from 19 countries. At the largest rheumatologist EULAR 2022 conference in June 2022, the results of the long-term safety and efficacy study of Artlegia CREDO4 were presented.
“Our global mission is to increase the availability of advanced therapies for patients not only in Russia, but also abroad. We are pleased that our partner at EAEU, Kazakhstan’s healthcare system will receive an effective tool to combat serious autoimmune disorders,” said Vasily Ignatiev, CEO of R-Pharm.
Olokizumab was registered by the Russian Ministry of Health in the spring of 2020 under the trade name Artlegia, and in the winter of the same year the drug was registered in the Republic of Azerbaijan.